27 results on '"Ommen, Hans B."'
Search Results
2. Measurable Residual Disease Monitoring of SPAG6, ST18, PRAME, and XAGE1A Expression in Peripheral Blood May Detect Imminent Relapse in Childhood Acute Myeloid Leukemia
3. Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML
4. The kinetics of relapse in DEK-NUP214-positive acute myeloid leukemia patients
5. Relapse kinetics in acute myeloid leukaemias with MLL translocations or partial tandem duplications within the MLL gene
6. hMICL and CD123 in combination with a CD45/CD34/CD117 backbone – a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia
7. Cell sorting enables interphase fluorescence in situ hybridization detection of low BCR-ABL1 producing stem cells in chronic myeloid leukaemia patients beyond deep molecular remission
8. Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse
9. Workstation benchmark of Spark Capable Genome Analysis ToolKit 4 Variant Calling
10. Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia
11. Persistent altered fusion transcript splicing identifies RUNX1-RUNX1T1+ AML patients likely to relapse
12. Case report: Exome sequencing identifies T-ALL with myeloid features as a IKZF1-struck early precursor T-cell malignancy
13. ADVANCING THE MRD CONCEPT IN ACUTE MYELOID LEUKEMIA
14. qPCR MRD Monitoring in Peripheral Blood May Predict Hematological Relapse in Pediatric Acute Myeloid Leukemia
15. Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia
16. Relapse kinetics in acute myeloid leukaemias withMLLtranslocations or partial tandem duplications within theMLLgene
17. Cell sorting enables interphase fluorescencein situhybridization detection of lowBCR-ABL1producing stem cells in chronic myeloid leukaemia patients beyond deep molecular remission
18. hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia
19. Persistent altered fusion transcript splicing identifiesRUNX1-RUNX1T1+ AML patients likely to relapse
20. Identification of the JAK/STAT Signaling Pathway as a Valid Therapeutic Target of T(8;21) Acute Myeloid Leukemia Using Combined Gene Expression and Promoter Occupancy Profiling.
21. Relapse Prediction in AML Patients in Complete Remission Using WT1 as a Molecular Marker: Development of a Mathematical Model To Predict Time from Molecular to Clinical Relapse and Define Optimal Sampling Intervals.
22. Loss of Heterozygosity (LOH) of the NUP98 Gene Is an Adverse Prognostic Factor in Acute Myeloid Leukemia (AML).
23. h MICL and CD123 in combination with a CD45/ CD34/ CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia.
24. Cell sorting enables interphase fluorescence in situ hybridization detection of low BCR-ABL 1 producing stem cells in chronic myeloid leukaemia patients beyond deep molecular remission.
25. Measurable Residual Disease Monitoring of SPAG6, ST18, PRAME, and XAGE1AExpression in Peripheral Blood May Detect Imminent Relapse in Childhood Acute Myeloid Leukemia
26. Co-shared genomic alterations within tumors from patients with both myeloproliferative neoplasms and lymphoma.
27. Case report: Exome sequencing identifies T-ALL with myeloid features as a IKZF1 -struck early precursor T-cell malignancy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.